(BWAY) BrainsWay Ltd. Company Overview

What does BrainsWay do?

BrainsWay Ltd. is an Israel-headquartered medical-device company focused on noninvasive neurostimulation for mental-health disorders. Its American depositary shares trade on Nasdaq and its ordinary shares trade on the Tel Aviv Stock Exchange under BWAY. The company’s core asset is Deep Transcranial Magnetic Stimulation, or Deep TMS, a platform that uses proprietary H-Coils to stimulate neural networks deeper and across a broader brain volume than conventional figure-eight-coil TMS. The treatment is delivered in a clinic without anesthesia or hospitalization. BrainsWay’s official company overview frames the mission as expanding access to advanced neuroscience-based care.

Which treatments and customers define the company?

The commercial platform addresses major depressive disorder, including anxious depression and expanded age groups; obsessive-compulsive disorder; and smoking addiction. Different H-Coil helmets let a clinic use one base system across multiple protocols. Customers include psychiatric practices, hospitals, medical centers, outpatient mental-health networks, and distributors outside the United States. It had 49 U.S. employees and 80 Israel-based employees at year-end 2025.

How does BrainsWay make money?

BrainsWay monetizes one clinical platform through several commercial structures rather than through a single equipment-sale model. It sells systems outright, leases them under fixed-fee arrangements, charges for sale-related services and extended warranties, and can use variable or pay-per-use structures. A lease reduces the clinic’s upfront barrier and gives BrainsWay contracted revenue. The 2025 Form 20-F reports that 39% of the global MDD installed base used the fixed-fee lease model at December 31, 2025, while 61% used the sales model.

Which revenue stream is largest?

Why is the leasing shift strategically important?

Management increasingly describes BrainsWay as an annual-recurring-revenue business. About 70% of customer engagements signed in recent quarters were structured as multi-year leases as of the fourth quarter of 2025. Remaining performance obligations, which represent contracted revenue not yet recognized, rose to about $75 million by March 31, 2026. That amount exceeded FY2025 revenue and gives visibility beyond shipments. BrainsWay retains leased systems, recognizes revenue over time, and supports customers throughout the contract.

What did BrainsWay’s latest quarter show?

The quarter ended March 31, 2026 showed faster growth and stronger operating leverage than the 2025 annual baseline. Revenue increased 35% year over year to $15.5 million, while operating income rose to $2.0 million from $0.6 million. Net income more than doubled to $2.3 million, and diluted earnings per share increased to $0.06 from $0.02. BrainsWay’s first-quarter 2026 results also reported record net shipments of 117 systems, up 44%, and an installed base of about 1,820 systems.

Is growth translating into operating leverage?

Q1 2026 operating expenses grew about 20%, slower than revenue growth of 35%. Selling and marketing was $4.9 million, R&D was $2.9 million, and G&A was $1.9 million. The resulting 12.9% operating margin approached 2026 guidance of 13% to 14%.

Which turning points still shape BrainsWay today?

BrainsWay’s history is a sequence of regulatory and commercial de-risking steps. FDA clearances created markets; reimbursement expanded access; leasing lowered adoption friction; and recent investments extend the company toward a broader mental-health ecosystem.

How did the platform move from invention to recurring revenue?

1. 2003
   BrainsWay was founded around Deep TMS and H-Coil intellectual property, establishing the platform that still anchors every commercial product.
2. 2013
   FDA clearance for major depressive disorder opened the core U.S. market and created the reimbursement base for clinical adoption.
3. 2018
   De novo clearance for OCD demonstrated that one platform could support a second psychiatric indication.
4. 2020-2021
   Smoking-addiction clearance and the anxious-depression label expansion broadened differentiation beyond standard depression TMS.
5. 2023
   Hadar Levy became chief executive after prior service as CFO and North America general manager, aligning leadership with both financial discipline and U.S. commercialization.
6. 2024-2025
   Late-life and adolescent depression expansions plus FDA clearance of the accelerated SWIFT protocol enlarged eligible populations and improved clinic-throughput potential.
7. 2025
   The Neurolief investment added exposure to at-home neuromodulation, complementing BrainsWay’s in-clinic platform.
8. 2026
   Record shipments, rising RPO, provider-network investments, and continued clinical work shifted the strategic narrative from proof of technology toward scaled execution.

What gives BrainsWay a competitive advantage?

BrainsWay’s moat is a portfolio rather than one isolated patent. It combines differentiated coil geometry, regulatory clearances based on clinical evidence, an installed base that can accept additional helmets, reimbursement progress, provider training, and enterprise-account relationships. Its technology description explains how the H-Coil is designed for deeper and broader stimulation than traditional TMS.

Why does the H-Coil platform matter?

The 2025 annual report lists multiple patent families covering H-Coils, multichannel stimulation, rotational-field TMS, closed-loop stimulation, and future designs. Some early licensed patents expire in 2026, but other owned or licensed families extend into 2030-2039. This layered portfolio matters because any single expiring patent does not define the entire competitive position. Still, rivals may design around claims or use BrainsWay’s FDA classifications as predicates for their own clearances.

How do reimbursement and installed base reinforce the moat?

The May 2026 investor deck reported customer retention above 93%, more than 1,800 treatment centers, and a 1.3 times book-to-bill ratio. A growing installed base increases the value of service, renewals, and add-on indications. Reimbursement reduces patient and clinic friction: the annual report estimated that more than 90% of privately insured U.S. adult lives had MDD coverage, while OCD had over 86 million covered lives as of March 2026.

Who competes with BrainsWay, and where is its market position strongest?

BrainsWay competes with direct TMS rivals such as Neuronetics, MagVenture, Magstim, Neurocare, Nexstim, Magnus Medical, and Ampa. Substitutes include drugs, psychotherapy, invasive procedures, and at-home neurostimulation. Buyer criteria include efficacy, safety, convenience, reimbursement, price, and provider economics.

Where does BrainsWay differentiate from traditional TMS?

How financially strong is BrainsWay?

BrainsWay entered 2026 with a much stronger financial profile than its historical loss record suggests. FY2025 revenue grew 27.3% to $52.2 million, gross profit reached $39.4 million, and operating profit increased to $4.3 million from $1.4 million in FY2024. Net income was $7.6 million, although $3.4 million of net finance income contributed materially. Operating cash flow reached $17.5 million, helped by a $9.3 million increase in deferred revenue, which is economically consistent with the growth of multi-year contracts.

What do margins and cash conversion reveal?

The cash-flow figure should not be treated as a normalized run rate because deferred revenue can move sharply between periods. Q1 2026 illustrates that volatility: operating cash flow was $1.2 million versus $5.0 million a year earlier because the prior-year quarter included a $6.3 million deferred-revenue increase. The company nevertheless reported an eleventh consecutive quarter of positive free cash flow in its May 2026 deck.

How is capital being allocated?

At March 31, 2026, BrainsWay held $58.6 million of cash plus $0.3 million of restricted cash and reported no conventional debt, although it had $6.7 million of lease liabilities and $6.0 million of liabilities related to development grants. The decline from $68.0 million at year-end 2025 primarily reflected investments rather than operating losses. The company completed a $6 million milestone-based convertible loan to Neurolief, bringing that exposure to $11 million, and deployed $8.5 million into financial assets in Q1 2026.

The strategy accelerated after quarter-end. BrainsWay announced a $500,000 preferred investment in Sound Minds Behavioral and, on July 20, 2026, a $3 million minority investment in Radial Health. These provider-network positions aim to expand awareness, clinic infrastructure, and access without BrainsWay acquiring or consolidating the operators.

Who owns BrainsWay, and how does governance matter?

BrainsWay has one class of ordinary shares, with one vote per share, and no disclosed unequal-voting founder structure. Economic ownership and voting influence are therefore aligned. As of March 23, 2026, the company had 40,033,026 ordinary shares outstanding. Nasdaq-traded ADSs represented about 46.6% of those shares, while the remainder was principally represented through the Israeli market and nominee system.

Which holders have the greatest disclosed influence?

Hadar Levy has served as chief executive since February 2023 after leading North America and previously serving as CFO. His disclosed beneficial ownership was below 1% at March 23, 2026, but his compensation includes multi-year options and restricted share units. The board’s ownership is more significant than the CEO’s, so researchers should examine related-party approvals, strategic-investment discipline, and board independence rather than assuming founder-led control.

What opportunities and risks could change BrainsWay’s outlook?

The upside case rests on converting clinical and reimbursement milestones into higher system placements, greater utilization, and recurring revenue. The risk case is that demand, payer coverage, evidence, execution, or customer concentration fails to support the planned operating leverage. BrainsWay’s FY2025 results set 2026 guidance of $66 million to $68 million of revenue, 13% to 14% operating margin, and $12 million to $14 million of adjusted EBITDA.

Which growth drivers are most credible?

Which risks are most material?

Which KPIs matter most for valuation?

A BrainsWay valuation should separate one-time system sales from leases, contracted performance obligations, services, and strategic investments. Revenue growth, recurring-revenue quality, operating leverage, and reinvestment therefore need separate treatment. The most useful DCF approach builds revenue from system placements and contract conversion, then tests whether gross margin can remain around 75% as operating expenses grow more slowly than revenue.

How should researchers connect operating data to a DCF?

Terminal assumptions deserve caution. BrainsWay has a large addressable market, but long-run growth depends on payer support, clinical evidence, competition, and the durability of its intellectual property. A reasonable model should therefore test slower RPO growth, lower system shipments, gross-margin pressure, higher ongoing R&D, and working-capital reversals rather than extrapolating the strongest recent quarter indefinitely.

What is the key takeaway from BrainsWay analysis?

BrainsWay matters because it has crossed an important threshold for a specialized medical-device company: its core platform is clinically differentiated, commercially scaling, profitable, cash-generative, and increasingly supported by multi-year contracts. FY2025 revenue reached $52.2 million, Q1 2026 revenue grew 35%, gross margin held near 75%, and RPO rose to $75 million. Those facts suggest that adoption is moving beyond isolated device placements.

The business is not de-risked. One customer generated 34% of FY2025 revenue; U.S. reimbursement drives demand; alternatives include other coils, protocols, drugs, and home devices; and minority-investment returns remain unproven. BrainsWay must preserve differentiation while proving that leases, enterprise accounts, and provider partnerships create durable cash flow.